B. Chewaskulyong

Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset

Byoung Chul Cho, B. Chewaskulyong, Ki Hyeong Lee et al. · Journal of Thoracic Oncology · 2018 · 136 citations · Full text

Medicine, Oncology, Pharmacology +7

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

Sendhilnathan Ramalingam, J.E. Gray, Yuichiro Ohe et al. · Annals of Oncology · 2019 · 68 citations · Full text

Medicine, Oncology, Pharmacology +8

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC

Yi‐Long Wu, Nagahiro Saijo, Sumitra Thongprasert et al. · Lung Cancer · 2016 · 56 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA

Sundar Ramalingam, Thanyanan Reungwetwattana, B. Chewaskulyong et al. · Annals of Oncology · 2017 · 35 citations · Full text

Medicine, Oncology, Pharmacotherapy +5

Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3

Jhanelle E. Gray, Aleksandra Markovets, Thanyanan Reungwetwattana et al. · Journal of Thoracic Oncology · 2024 · 22 citations · Full text

Medicine, Molecular Medicine, Oncology +16